Effectiveness of Azithromycin As Therapy Covid-19

Abstract

Corona virus infection 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. Covid-19 has been declared a pandemic by the WHO, where the scale of the spread of the disease occurs globally. Azithromycin alone and its combination with hydroxychloroquine has been proposed as a treatment that can improve the prognosis of COVID-19. The purpose of this review is to determine the use of doses and how long azithromycin is active in COVID-19 patients. This research method uses a literature review of articles through internet searches by accessing the database from the google scholar site, pubmed. The object of this research is a scientific article published in the period 2017-2021 and relates to the effectiveness of azithromycin as a therapy to treat Covid-19 infection in humans. The results of the literature study show that Azithromycin has the potential as a therapy in COVID-19 patients, either alone or in combination. The average duration of azithromycin administration was 5 days, of which 500 mg was the loading dose followed by 250 mg for the next 4 days. The effectiveness of Azithromycin either alone or in combination with hydroxychloroquine (HCQ) showed effectiveness in reducing viral load where the decline began on day 6 and complete recovery of the patient was achieved on day 10 to day 12. The conclusion of this study is that Azithromycin has the potential as a therapy in COVID-19 patients, either alone or in combination.